Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Yea Christopher, Chief Development Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), sold 30,250 shares of common stock on July 9, 2025, at a price of $15.6925, totaling $474,698. The sale comes as the stock trades near its 52-week high of $16.32, having delivered an impressive 97.58% return over the past six months. InvestingPro analysis indicates the stock is currently showing overbought signals.
On July 8, 2025, Yea Christopher also acquired 60,000 shares of KalVista Pharmaceuticals, Inc. common stock. These shares were earned upon the vesting of performance stock units granted on January 11, 2023, with each unit representing the right to receive one share of common stock.
Following the sale, Yea Christopher directly owns 127,939 shares of KalVista Pharmaceuticals.
In other recent news, Kalvista Pharmaceuticals has announced the FDA approval of Ekterly (sebetralstat) as the first oral on-demand treatment for hereditary angioedema (HAE) attacks. This milestone allows the company to launch Ekterly in the U.S. with a wholesale acquisition cost of $16,720 per dose, packaged to cover two HAE attacks. Analysts have responded positively, with Leerink Partners maintaining an Outperform rating and setting a price target of $20, while JMP Securities raised its price target to $27, projecting peak sales of $740 million. BofA Securities also increased its price target to $37, citing Ekterly’s unique market position as a driver for patient uptake. Stifel reiterated a Buy rating with a $39 price target, noting the favorable labeling and potential for market adoption. Kalvista has launched patient support programs, including a Quick Start initiative, to facilitate the drug’s entry into the market. Internationally, the company anticipates an EMA decision and a targeted launch in Germany in the latter half of 2025, with subsequent launches in Japan and the UK. The analysts’ consensus highlights the potential for Ekterly to capture significant market share as the only oral treatment available for HAE attacks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.